One Health Approach to Antimicrobial Stewardship in Companion Animals – Tufts Vet School’s Claire Fellman, D.V.M., Ph.D., DACVIM (SA), DACVCP
Tufts University Cummings School of Veterinary Medicine’s Claire Fellman, D.V.M., Ph.D., DACVIM (SA), DACVCP is interested in One Health approaches to antimicrobial stewardship in veterinary medicine.
The Challenge of Antibiotics Stewardship in Low Income Countries: The Case of the Democratic Republic of Congo – Tufts Vet’s Diafuka Saila-Ngita, DVM, MSc, PhD
Tufts University Cummings School of Veterinary Medicine’s Diafuka Saila-Ngita, DVM, MSc, PhD, is interested in addressing the challenges of antimicrobial stewardship in low-income nations such as the Democratic Republic of Congo.
Developing a Mycobacterial Research Agenda – Tufts Medical Center’s Husain Poonawala, MBBS, MPH
Tufts Medical Center’s Husain Poonawala, MBBS, MPH, is interested in tuberculosis and non-tuberculous mycobacteria, how next-generation sequencing and novel diagnostic methods can be integrated into clinical care.
Antimicrobial Stewardship in Jails and Prisons: When Will Then be Now? – Tufts Medical Center’s Alysse Wurcel, MD, MS
Infections of all kinds—tuberculosis, dental infections, HIV, sexually transmitted infections, COVID-19, and more—are common in jails and prisons, making these facilities places where antibiotics are frequently prescribed. Unfortunately, sometimes antibiotics are prescribed even though they are not clinically indicated, the
Microbial Theranostics: A Resistance Combating Strategy – Mayo Clinic’s Robin Patel, MD
In the research laboratory, Dr. Patel and her colleagues focus on biofilms, which cause a large number of infections in modern clinical practice, such as prosthetic joint infection and endocarditis. She and her team are unraveling the process of biofilm
How HAMLET, a Human Milk Protein, Kills Bacteria and Reverses Antibiotic Resistance – Lund University’s Anders P. Håkansson, PhD
Did you know that a human breast milk protein complex called HAMLET can help reverse the antibiotic resistance of bacterial species, including penicillin-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus? Lund University’s Anders P. Håkansson, PhD, presented on his work with
Phage Prophylaxis of Cholera – Tufts University’s Andrew Camilli, PhD
Bacteriophages are viruses that specifically target and kill bacteria, preventing bacterial infections, and Dr. Andrew Camilli and his lab study the bacteriophages that kill V. cholerae. Dr. Camilli is also co-founder and scientific advisor to PhagePro, Inc., a Boston-based startup aiming
From Detection to Predicting Infectious Disease and Antibiotic Resistance Outcomes: Employing Experimental Evolution, Omics-Stress Mapping and Computational Biology to Determine and Predict What Matters in Antibiotic Resistance
Tim van Opijnen, PhD, an Associate Professor of Biology at Boston College and an Affiliate member of the Levy CIMAR, presented for our May 2021 Levy CIMAR Science Lunch on his group's work on antimicrobial resistance. His talk was titled,
Monoclonal Ab treatment for SARS CoV2 infection
Veterinary pathologist Amanda J. Martinot (DVM, MPH, PhD) of the Tufts University Cummings School of Veterinary Medicine presented for our Monthly Science Meeting on Thursday, January 28, on two articles of interest in the COVID-19 pandemic: The first on the
Trials and Tribulations of Antimicrobial Drug Development: Assessing the Economic and Political Landscape
As an internationally recognized expert on drug development science and policy, the Levy CIMAR's Dr. Kenneth I. Kaitin writes and speaks regularly on factors that contribute to the slow pace and high cost of pharmaceutical R&D and efforts to improve